PBLS.US Parabilis Medicines, Inc. Common Stock

Healthcare Biotechnology USA Stocks
28.79 USD
Close of Nov 15, 2026
22.66 42.49
Market cap
USD 3.56B
P/E
-
P/B
3.40x
ROE
-18.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PBLS.US undervalued?

Graham number

The Graham number of Parabilis Medicines, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Parabilis Medicines, Inc. Common Stock fundamental analysis

No fundamental analysis for Parabilis Medicines, Inc. Common Stock yet.

Parabilis Medicines, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Parabilis Medicines, Inc. Common Stock

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, wit…

Full company profile